Conducive target range of breast cancer: Hypoxic tumor microenvironment

Cheng, Wen; Xiao, Xian; Yang, Lihong; Cao, Qingqing; Wang, Chaoran; Li, Xiaojiang; Jia, Yulin

doi:10.3389/fonc.2022.978276

Cited by 3 publications

(2 citation statements)

References 189 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This activation results in E-cadherin suppression and vimentin induction in BC, with HIF-1a inhibition markedly increasing E-cadherin levels (133). While E-cadherin encourages collective migration of mixed E/M phenotypes by inhibiting TGF-b, TGF-b activation promotes single-cell migration (134). CSF-1, a regulator of EMT, is influenced by hypoxia.…”

Section: Invasion and Metastasismentioning

confidence: 99%

Hypoxia-inducible factor in breast cancer: role and target for breast cancer treatment

Zhi,

Chen,

Huang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Globally, breast cancer stands as the most prevalent form of cancer among women. The tumor microenvironment of breast cancer often exhibits hypoxia. Hypoxia-inducible factor 1-alpha, a transcription factor, is found to be overexpressed and activated in breast cancer, playing a pivotal role in the anoxic microenvironment by mediating a series of reactions. Hypoxia-inducible factor 1-alpha is involved in regulating downstream pathways and target genes, which are crucial in hypoxic conditions, including glycolysis, angiogenesis, and metastasis. These processes significantly contribute to breast cancer progression by managing cancer-related activities linked to tumor invasion, metastasis, immune evasion, and drug resistance, resulting in poor prognosis for patients. Consequently, there is a significant interest in Hypoxia-inducible factor 1-alpha as a potential target for cancer therapy. Presently, research on drugs targeting Hypoxia-inducible factor 1-alpha is predominantly in the preclinical phase, highlighting the need for an in-depth understanding of HIF-1α and its regulatory pathway. It is anticipated that the future will see the introduction of effective HIF-1α inhibitors into clinical trials, offering new hope for breast cancer patients. Therefore, this review focuses on the structure and function of HIF-1α, its role in advancing breast cancer, and strategies to combat HIF-1α-dependent drug resistance, underlining its therapeutic potential.

show abstract

Section: Invasion and Metastasismentioning

confidence: 99%

Hypoxia-inducible factor in breast cancer: role and target for breast cancer treatment

Zhi,

Chen,

Huang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…In the hypoxic tumor microenvironment, more aggressive and treatment-resistant tumor phenotypes can emerge, promoting tumor metastasis, suppressing immune activity, increasing tumor drug resistance, and reducing the effectiveness of anticancer drugs. 28 Intratumoral hypoxia is usually induced by abnormalities in microvascular structure and function. 29 The hypoxic response of cancer cells is attributed to hypoxia-inducing factors (HIFs).…”

Section: The Breast Tumor Microenvironmentmentioning

confidence: 99%